Biological E's Covid-19 vaccine Corbevax likely to be launched by Sept-end

Biological E is expected to apply for an Emergency use License (EUL) by August-end

vaccine, vaccination, coronavirus, covid-19
ANI General News
2 min read Last Updated : Jul 26 2021 | 3:24 PM IST

The Hyderabad-based pharmaceutical company Biological E is expected to launch its COVID-19 vaccine Corbevax by September end in India, said sources on Monday.

Sources told ANI that the company has started its phase 3 clinical trials.

Biological E's COVID-19 vaccine Corbevax has been booked by the government before preclinical stage phase 3 studies.

In the latest written reply, Union Minister of State for Health, Dr Bharati Pravin Pawar said that the Government of India has also provided financial assistance to domestic vaccine manufacturer Biological E which is currently in advance phase 3 clinical trials for 'at-risk manufacturing' of the COVID-19 vaccine.

Biological E is expected to apply for an Emergency use License (EUL) by August end and will be supplying 300 million doses to the Government of India by December 2021.

This comes a day after an expert panel has recommended the government to increase the vaccination and stick to non-pharmacological interventions, in a bid to curtail a possible third wave of COVID-19 as speculated by many health experts and COVID management bodies which might hit the country by September.

Speaking to ANI, one of the experts in the government-authorised panel suggested it has "recommended government to increase vaccination and stick to non-pharmacological interventions such as COVID-19 appropriate behaviour, wearing a mask, social distancing, and containment zone."

As per the panel's recommendations, the key is to strengthen health infrastructure and prepare adequately so that up to 4 lakh cases every day can be handled. In addition, routine services are also to be maintained, they said.

This will need 2 lakh additional ICU beds with 1 lakh ventilator beds. This will be in addition to vaccinations and Covid appropriate behavior," sources told ANI.

In order to tackle the COVID-19 situation and improve the health infrastructure of the country, the government has announced a Rs 23,000-crore COVID management package. States have already been directed to send their plans for building health infrastructure to the Union Health Ministry. Money will be given to the state immediately as per its plan.

Meanwhile, India's COVID-19 vaccination coverage exceeded 43.51 crores on Sunday. Cumulatively,43,51,96,001 vaccine doses have been administered through 52,95,458 sessions, as per the provisional report till 8 am today. 18,99,874 vaccine doses were administered in the last 24 hours, said the Union Health Ministry on Monday.

The new phase of universalisation of COVID-19 vaccination commenced from June 21, June.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jul 26 2021 | 3:23 PM IST

Next Story